Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit? (Q38055067)

27 August 2017

title

Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit? (English)

1 reference

27 August 2017

2

1 reference

27 August 2017

3

Ian F Tannock

1 reference

27 August 2017

Man Yu

1

1 reference

27 August 2017

publication date

1 June 2013

1 reference

Cancer and Metastasis Reviews

27 August 2017

published in

1 reference

27 August 2017

volume

32

1 reference

27 August 2017

issue

1-2

1 reference

27 August 2017

page(s)

211-227

1 reference

Advances in the molecular detection of ABC transporters involved in multidrug resistance in cancer

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

ABC proteins protect the human body and maintain optimal health

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Drug binding in human P-glycoprotein causes conformational changes in both nucleotide-binding domains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Importance of P-glycoprotein at blood-tissue barriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

The physiological function of drug-transporting P-glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

A novel in vivo regulatory role of P-glycoprotein in alloimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

ATP-binding cassette (ABC) transporters in normal and pathological lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Basal Membrane Localization of MRP1 in Human Placental Trophoblast

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Transport of glutathione and glutathione conjugates by MRP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

The role of the multidrug resistance protein-1 in modulation of endothelial cell oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

A multidrug resistance transporter from human MCF-7 breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Structure and Function of the Human Breast Cancer Resistance Protein (BCRP/ABCG2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

ABCG2 transports sulfated conjugates of steroids and xenobiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Resistance mechanisms to cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Moderate Increase in Mdr1a/1b Expression Causes In vivo Resistance to Doxorubicin in a Mouse Model for Hereditary Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

How can we best use structural information on P-glycoprotein to design inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer Research Group, and the Aberdeen Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Enhancement of cytotoxicity of natural product drugs against multidrug resistant variant cell lines of human head and neck squamous cell carcinoma and breast carcinoma by tesmilifene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Tesmilifene may enhance breast cancer chemotherapy by killing a clone of aggressive, multi-drug resistant cells through its action on the p-glycoprotein pump

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

A phase I and pharmacokinetic study of CBT-1 as a multidrug resistance modulator in the treatment of patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

ABC efflux pump-based resistance to chemotherapy drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Pheophorbide a is a specific probe for ABCG2 function and inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

A "silent" polymorphism in the MDR1 gene changes substrate specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

A novel MDR1 GT1292-3TG (Cys431Leu) genetic variation and its effect on P-glycoprotein biologic functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

MDR1 genotype-related pharmacokinetics: fact or fiction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Drug resistance and the solid tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

The influence of expression of P-glycoprotein on the penetration of anticancer drugs through multicellular layers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Microregional effects of gemcitabine in HCT-116 xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Influence of cell concentration in limiting the therapeutic benefit of P-glycoprotein reversal agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

High-affinity monoclonal antibodies against P-glycoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Expression of a human complementary DNA for the multidrug resistance gene in murine hematopoietic precursor cells with the use of retroviral gene transfer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Transgenic mice that express the human multidrug-resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Complete inhibition of P-glycoprotein by simultaneous treatment with a distinct class of modulators and the UIC2 monoclonal antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Pgp inhibition by UIC2 antibody can be followed in vitro by using tumor-diagnostic radiotracers, 99mTc-MIBI and 18FDG

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Regression of established tumors expressing P-glycoprotein by combinations of adriamycin, cyclosporin derivatives, and MRK-16 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Possibility of the reversal of multidrug resistance and the avoidance of side effects by liposomes modified with MRK-16, a monoclonal antibody to P-glycoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Immunization with liposome-anchored pegylated peptides modulates doxorubicin sensitivity in P-glycoprotein-expressing P388 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Anti-Cripto Mab inhibit tumour growth and overcome MDR in a human leukaemia MDR cell line by inhibition of Akt and activation of JNK/SAPK and bad death pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Gli1 is a potential target for alleviating multidrug resistance of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Overcoming drug resistance by regulating nuclear receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Human pregnane X receptor and resistance to chemotherapy in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Down-regulation of pregnane X receptor contributes to cell growth inhibition and apoptosis by anticancer agents in endometrial cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Reversal of drug resistance in breast carcinoma cells by anti-mdr1 ribozyme regulated by the tumor-specific MUC-1 promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Multidrug resistance inhibition by antisense oligonucleotide against MDR1/mRNA in P-glycoprotein expressing leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Recent attempts at RNAi-mediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Stable and complete overcoming of MDR1/P-glycoprotein-mediated multidrug resistance in human gastric carcinoma cells by RNA interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Complete in vivo reversal of the multidrug resistance phenotype by jet-injection of anti-MDR1 short hairpin RNA-encoding plasmid DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

In vivo reversal of P-glycoprotein-mediated multidrug resistance by efficient delivery of stealth RNAi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

The siRNA targeted to mdr1b and mdr1a mRNAs in vivo sensitizes murine lymphosarcoma to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Promises and challenges in developing RNAi as a research tool and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Nanomedicine in cancer therapy: innovative trends and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel -polymer micelles to overcome multi-drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Biodistribution and pharmacokinetic analysis of Paclitaxel and ceramide administered in multifunctional polymer-blend nanoparticles in drug resistant breast cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Augmentation of therapeutic efficacy in drug-resistant tumor models using ceramide coadministration in temporal-controlled polymer-blend nanoparticle delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Gr

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Enhanced chemotherapy of cancer using pH-sensitive mesoporous silica nanoparticles to antagonize P-glycoprotein-mediated drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and 5-bromotetrandrine in xenograft nude-mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Daunorubicin-loaded magnetic nanoparticles of Fe3O4 overcome multidrug resistance and induce apoptosis of K562-n/VCR cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Curcumin Enhances Oral Bioavailability and Anti-Tumor Therapeutic Efficacy of Paclitaxel upon Administration in Nanoemulsion Formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

A folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9402-8

10.1007/S10555-012-9402-8

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1019497964

0 references

1 reference